Effect of Hachimijiogan against Renal Dysfunction and Involvement of Hypoxia-Inducible Factor-1α in the Remnant Kidney Model
Table 2
Physiological data of experimental animals.
Group
Body weight (g)
Kidney weight (g/100g BW)
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Urine volume (mL/day)
Baseline
Final
Baseline
Final
Baseline
Final
Baseline
Final
Sham
297.1 ± 11.0
325.5 ± 12.0
0.311 ± 0.04
121.4 ± 14.2
113.7 ± 10.8
56.4 ± 13.5
62.6 ± 16.2
5.7 ± 3.1
6.4 ± 2.8
Control
261.7 ± 22.9
291.6 ± 26.4*
0.331 ± 0.05
124.3 ± 5.8
127.7 ± 8.2
69.7 ± 6.7
59.1 ± 12.2
20.3 ± 6.6**
21.1 ± 6.1**
LD-HJG
253.6 ± 17.6
275.9 ± 24.3*
0.341 ± 0.03
132.9 ± 27.1
130.0 ± 17.2
74.2 ± 19.1
62.8 ± 16.2
17.6 ± 6.7**
14.1 ± 6.3**
HD-HJG
257.5 ± 16.6
295.6 ± 16.4*
0.354 ± 0.04
122.8 ± 15.6
126.3 ± 8.9
70.1 ± 17.3
56.9 ± 6.1
20.6 ± 8.3**
18.0 ± 7.1**
Candesartan
264.3 ± 14.6
276.1 ± 16.6*
0.343 ± 0.03
121.4 ± 14.6
119.7 ± 16.2
70.9 ± 15.8
58.5 ± 13.1
20.2 ± 13.4**
16.5 ± 12.8**
LD-HJG: low-dose hachimijiogan; HD-HJG: high-dose hachimijiogan. Baseline: before drug administration; Final: after 1 week of drug administration. Data represent mean ± S.D. ( n = 8–10). , versus sham group.